BLLNBillionToOne, Inc.
Is the price fair?
A demanding price: priced for a lot of growth and rich vs its sector.
Priced for ~33% a year FCF growth. The price already bakes in strong, sustained growth.
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
All from derived, as of Jun 30, 2026.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What BLLN's price assumes
BillionToOne, Inc. trades at 140× earnings against 35.2× for the median Diagnostics & Research name, more expensive than its own group.
Trailing P/E · Diagnostics & Research median 35.2 · 3.99× the median: the market pays up for this one
- Price / sales
- 13.0
Price / sales · today's price, trailing year to Jun 30, 2026
- Free cash flow yield
- 0.64%
Free cash flow yield · Diagnostics & Research median 3.7%
- Growth the price implies
- +33%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 9.62
- EV / EBITtoday's price, trailing year to Jun 30, 2026
- 109
- EV / salestoday's price, trailing year to Jun 30, 2026
- 11.8
- Healthcare median P/E509 names
- 26.2
- Diagnostics & Research median P/E33 names
- 35.2
- Free cash flow, trailing twelve months
- $33M
- Market capitalisation
- $5.16B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
The closest names by size in the same industry